Shipping to United States We Offer Worldwide Shipping
Login Wishlist

2’’-O-Coumaroyljuglanin

$905

  • Brand : BIOFRON

  • Catalogue Number : AV-B03146

  • Specification : 97%

  • CAS number : 67214-05-5

  • Formula : C29H24O12

  • Molecular Weight : 564.49

  • PUBCHEM ID : 23265178

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

AV-B03146

Analysis Method

HPLC,NMR,MS

Specification

97%

Storage

2-8°C

Molecular Weight

564.49

Appearance

Yellow powder

Botanical Source

Structure Type

Flavonoids

Category

Standards;Natural Pytochemical;API

SMILES

C1=CC(=CC=C1C=CC(=O)OC2C(C(OC2OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC=C(C=C5)O)CO)O)O

Synonyms

5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-3-yl 2-O-[(2E)-3-(4-hydroxyphenyl)-2-propenoyl]-α-L-arabinofuranoside/4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[[2-O-[(2E)-3-(4-hydroxyphenyl)-1-oxo-2-propen-1-yl]-α-L-arabinofuranosyl]oxy]-

IUPAC Name

[(2S,3R,4S,5S)-2-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-3-yl]oxy-4-hydroxy-5-(hydroxymethyl)oxolan-3-yl] (E)-3-(4-hydroxyphenyl)prop-2-enoate

Applications

Density

1.7±0.0 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

302.0±0.0 °C

Boiling Point

903.5±0.0 °C at 760 mmHg

Melting Point

InChl

InChI=1S/C29H24O12/c30-13-21-24(36)28(40-22(35)10-3-14-1-6-16(31)7-2-14)29(39-21)41-27-25(37)23-19(34)11-18(33)12-20(23)38-26(27)15-4-8-17(32)9-5-15/h1-12,21,24,28-34,36H,13H2/b10-3+/t21-,24-,28+,29-/m0/s1

InChl Key

FMIKFIFUIPULCE-QRJDQECMSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:67214-05-5) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

11308270

Abstract

Darbepoetin alfa is a novel erythropoiesis stimulating protein (NESP), which stimulates erythropoiesis by the same mechanism as recombinant human erythropoietin (rHuEPO). NESP has been shown to be safe and efficacious in patients with chronic renal failure. NESP is biochemically distinct from rHuEPO, due to its increased sialic acid content. NESP has an approximately 3-fold greater half-life. rHuEPO has been shown to be safe and effective for the treatment of chemotherapy-induced anaemia. This study assessed the safety and efficacy of NESP administered once per week, under the supervision of a physician, to patients with solid tumours who were receiving multicycle chemotherapy for up to 12 weeks. Three dose cohorts are presented in this sequential, unblinded and dose-escalating study. Thirteen to 59 patients received NESP (0.5, 1.5 or 2.25?mcg?kg?1wk?1) in each cohort. Patients were monitored for adverse events, including antibody formation to NESP and for effects on haemoglobin. NESP appeared to be well tolerated. Adverse events were similar across all cohorts and were consistent with the population being studied. No antibody formation was detected over the 16-week study period and follow-up. A dose-response relationship was evident for NESP and multiple measures of efficacy, including proportion of patients responding to NESP and the mean change in haemoglobin by week 4 and end of treatment for NESP 0.5, 1.5 and 2.25 mcg kg?1wk?1cohorts (mean change in haemoglobin at end of treatment was 1.24, 1.73 and 2.15 g dl?1respectively). Controlled studies of this agent at higher doses and less frequent schedules of administration are ongoing. ? 2001 Cance Cancer Research Campaign

KEYWORDS

anaemia, cancer, chemotherapy, darbepoetin alfa, solid tumours, transfusion

Title

A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy

Author

J Glaspy,1 J Singh Jadeja,2 G Justice,3 J Kessler,4 D Richards,5 L Schwartzberg,6 J Rigas,7 D Kuter,8 D Harmon,8 D Prow,9 G Demetri,10 D Gordon,11 J Arseneau,12 A Saven,13 H Hynes,14 R Boccia,15 J O'Byrne,16 and A B Colowick16

Publish date

2001 Apr; 8

PMID

9166001

Abstract

OBJECTIVE?To investigate the relation between measures of pain threshold and symptoms of distress to determine if fibromyalgia is a discrete construct/disorder in the clinic.
METHODS?627 patients seen at an outpatient rheumatology centre from 1993 to 1996 underwent tender point and dolorimetry examinations. All completed the assessment scales for fatigue, sleep disturbance, anxiety, depression, global severity, pain, functional disability, and a composite measure of distress constructed from scores of sleep disturbance, fatigue, anxiety, depression, and global severity?the rheumatology distress index (RDI).
RESULTS?In regression analyses, the RDI was linearly related to the count of tender points (r2=0.30). Lesser associations were found between the RDI and dolorimetry measurements (r2=0.08). The RDI was more strongly correlated with the two measures of pain threshold than any of the individual fibromyalgia symptom variables. In partial correlation analyses, all of the information relating to symptom variables was contained in the tender point count, and dolorimetry was not independently related to symptoms.
CONCLUSION?Tender points are linearly related to fibromyalgia variables and distress, and there is no discrete enhancement or perturbation of fibromyalgia or distress variables associated with very high levels of tender points. Although fibromyalgia is a recognisable clinical entity, there seems to be no rationale for treating fibromyalgia as a discrete disorder, and it would seem appropriate to consider the entire range of tenderness and distress in clinic patients as well as in research studies. The tender point count functions as a `sedimentation rate’ for distress, and is a better measure than the dolorimetry score.

Title

The relation between tender points and fibromyalgia symptom variables: evidence that fibromyalgia is not a discrete disorder in the clinic

Author

F. Wolfe

Publish date

1997 Apr

PMID

16623074

Abstract

Although hypertension affects all racial and ethnic groups, its prevalence is highest in the African-American community. The goal of Healthy People 2010 is to reduce hypertension among African Americans from 40% to 16%. Although current levels remain high, culturally sensitive, community-based clinical projects might be helpful in addressing this problem. The goal of this study was to assess whether a community-based clinic’s program was effective in improving blood pressure control among a sample of 134 African-American adults. The program design involved health education and physical fitness classes offered over a nine-month period, with blood pressure checks being conducted pre- and postphases to determine whether the program was effective in controlling high blood pressure. Health questionnaires were also administered pre- and posttest to assess whether health behaviors and perceived health status were influenced by the project. Two-thirds (70%) of the sample had high blood pressure at baseline and 43% at program conclusion. This was a statistically significant difference (p=0.003). Overall self-reported health survey results indicated improved health behaviors and health status changes. Findings suggest that culturally sensitive, community-based clinic programs that incorporate both health education and physical fitness might be effective in reducing hypertension among African Americans.

Title

Evaluating the impact of a hypertension program for African Americans.

Author

Angelia M. Paschal, Rhonda K. Lewis, Arneatha Martin, Donna Dennis Shipp, Donna Sanders Simpson

Publish date

2006 Apr